Should I buy Charles River Laboratories (CRL) stock or is it too late?
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $300 (+1.2 %), call made on August 8, 2026, maturing on August 8, 2027 (20 d ago).
Firm-by-firm track record on Charles River Laboratories
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Citigroup | 78 % | +43.0 % | 9 | $265 -11% |
| Morgan Stanley | 67 % | +37.6 % | 9 | $300 +1% |
| Jefferies | 86 % | +29.8 % | 14 | $195 -34% |
| Evercore ISI Group | 60 % | +21.6 % | 5 | $300 +1% |
| JP Morgan | 38 % | +7.0 % | 8 | $310 +5% |
| Goldman Sachs | 40 % | +4.4 % | 5 | $170 -43% |
| Baird | 50 % | +3.5 % | 10 | $199 -33% |
| UBS | 29 % | -5.3 % | 7 | $175 -41% |
✅ Reasons to believe
- 75% of analysts rate it a buy (Buy consensus, 8 ratings) — a sign of market conviction.
⚠️ Reasons to hesitate
- Even the most reliable firm on CRL, Jefferies (86% hit rate, 14 scored calls), only targets $195 (call made on September 9, 2025, maturing on September 9, 2026) (-34%) in its most recent call. The stock may already have run past its target.
- The consensus is not unanimous: of 8 ratings, 2 are neutral.
- Limited upside: the median target is only -2% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on CRL
Median target $291 (-2%) · 8 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Charles River Laboratories now?
We won't decide for you. The facts: 75% of analysts rate it a buy, median target $291 (-2%), and Jefferies (most reliable on CRL, 86%) targets $195. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Charles River Laboratories?
The stated upside is small: the median target ($291) sits just -2% from the price ($296) (most reliable on CRL: Jefferies, 86%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Charles River Laboratories still worth investing in?
It depends on the gap between the price ($296) and its estimated value: analysts target $291 on median (-2%), with 75% buys (most reliable on CRL: Jefferies, 86%). Cross-check with their real reliability on CRL and the cautions above. Information, not advice.
What's the main risk in buying CRL?
Even the most reliable firm on CRL, Jefferies (86% hit rate, 14 scored calls), only targets $195 (call made on September 9, 2025, maturing on September 9, 2026) (-34%) in its most recent call. The stock may already have run past its target.
→ Go deeper: the full Charles River Laboratories profile (consensus, analyst reliability, price target, performance).